Skip to main content

Table 2 AEs in patients receiving bilastine 20 mg in clinical trials

From: Bilastine: new insight into antihistamine treatment

Study Patients N. Duration Disease AEs in bilastine-treated group
Kuna P et al. [24] 683 SAR Any 24.7%
14 days   
   Headache 10.6%
   Somnolence 1.8%
   Fatigue 0.4%
   Dyspnoea 0.9%
Bachert C et a. [23] 721 SAR Any 28.3%
14 days   Headache 12.0%
   Somnolence 3.9%
   Fatigue 2.6%
Sastre J et al. [25] 650 PAR Any 23.4%
4 weeks   
   Headache 10.7%
   Somnolence 13.7%
Zuberbiert T et al. [29] 525 CIU Any 30.1%
28 days   Headache 12.1%
   Somnolence 5.8%
   Fatigue 2.9%
  1. SAR: seasonal allergic rhinitis; PAR: persistent allergic rhinitis, CIU: chronic idiopatic urticarial, AEs: adverse event.